Is Crop Life Scienc overvalued or undervalued?

As of 22 September 2025, the valuation grade for Crop Life Science has moved from fair to attractive, indicating a more favorable assessment of its market position. The company appears to be undervalued, with a PE ratio of 15.66, an EV to EBITDA ratio of 8.86, and a ROCE of 11.07%. In comparison to peers, UPL has a significantly higher PE ratio of 38.29, while BASF India stands at 48.96, both of which suggest that Crop Life Science is trading at a discount relative to these competitors.
The attractive valuation is further supported by its PEG ratio of 1.63, which is competitive when compared to peers like Sharda Cropchem, which has a PEG of 0.10, indicating that Crop Life Science offers a better growth potential relative to its price. Additionally, the company's recent stock performance has outpaced the Sensex, with a year-to-date return of 20.64% compared to the Sensex's 6.59%, reinforcing the notion that it is undervalued in the current market environment.